恶性胸膜间皮瘤靶向治疗进展

摘要/Abstract

摘要：恶性胸膜间皮瘤（MPM）是胸膜罕见的恶性肿瘤，由于其潜伏期约为20年，目前正是该疾病的高发阶段。由于该疾病发现时大部分已处于晚期，除了经典的培美曲塞联合顺铂一线化疗方案疗效确定之外，手术、放疗及二三线化疗疗效仍未知。近年来发展迅猛的分子靶向治疗又为MPM的个体化治疗提供了新的方向。

程蕾, 许亚萍, 毛伟敏. 恶性胸膜间皮瘤靶向治疗进展[J]. 国际肿瘤学杂志, 2014, 41(1): 52-55.

Cheng Lei, Xu Yaping, Mao Weimin. Molecular targeted therapy of malignant pleural mesothelioma[J]. Journal of International Oncology, 2014, 41(1): 52-55.

［1］ Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study［J］. J Clin Oncol, 2007, 25(17):24062413. ［2］ Kai K, D′Costa S, Sills RC, et al. Inhibition of the insulinlike growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines［J］. Cancer Lett, 2009, 278(1):4955. ［3］ Mezzapelle R, Miglio U, Rena O, et al. Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma［J］. Br J Cancer, 2013, 108(8): 17431749. ［4］ Suzuki Y, Murakami H, Kawaguchi K, et al. Activation of the PI3KAKT pathway in human malignant mesothelioma cells［J］. Mol Med Rep, 2009, 2(2):181188. ［5］ Opitz I, Soltermann A, Abaecherli M, et al. PTEN expression is a strong predictor of survival in mesothelioma patients［J］. Eur J Cardiothorac Surg, 2008, 33(3):502506. ［6］ Jahan T, Gu L, Kratzke R, et al. Vatalanib in malignant mesothelioma: a phase Ⅱ trial by the cancer and leukemia group B (CALGB 30107)［J］. Lung Cancer, 2012, 76(3):393396. ［7］ Garland LL, Chansky K, Wozniak AJ, et al. Phase Ⅱ study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509［J］. J Thorac Oncol, 2011, 6(11):19381945. ［8］ Buikhuisen WA, Burgers JA, Vincent AD, et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after firstline chemotherapy (NVALT 5): an openlabel, multicentre, randomised phase 3 study［J］. Lancet Oncol, 2013, 14(6):543551. ［9］ Pinto C, Ardizzoni A, Betta PG, et al. Expert opinions of the first italian consensus conference on the management of malignant pleural mesothelioma［J］. Am J Clin Oncol, 2011, 34(1):99109. ［10］ Nowak AK, Millward MJ, Creaney J, et al. A phase Ⅱ study of intermittent sunitinib malate as secondline therapy in progressive malignant pleural mesothelioma［J］. J Thorac Oncol, 2012, 7(9):14491456. ［11］ Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma［J］. Cancer, 2008,113(4):808814. ［12］ Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, doubleblind, placebocontrolled, randomized phase Ⅱ trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma［J］. J Clin Oncol, 2012, 30(20): 25092515. ［13］ Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of singleagent imatinib mesylate in malignant pleural mesothelioma［J］. Cancer Chemother Pharmacol, 2007, 59(1):149150. ［14］ Dudek AZ, Pang H, Kratzke RA, et al. Phase Ⅱ study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report［J］. J Thorac Oncol, 2012, 7(4):755759. ［15］ Hartman ML, Esposito JM, Yeap BY, et al. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma［J］. J Thorac Cardiovasc Surg, 2010, 139(5):12331240. ［16］ Hoda MA, Mohamed A, Ghanim B, et al. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy［J］. J Thorac Oncol, 2011, 6(5):852863. ［17］ Gregorc V, Zucali PA, Santoro A, et al. Phase Ⅱ study of asparagineglycineargininehuman tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma［J］. J Clin Oncol, 2010, 28(15):26042611. ［18］ Paik PK, Krug LM. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials［J］. J Thorac Oncol, 2010, 5(2):275279. ［19］ Scherpereel A, Berghmans T, Lafitte JJ, et al. Valproatedoxorubicin: promising therapy for progressing mesothelioma. A phase Ⅱ study［J］. Eur Respir J, 2011, 37(1):129135.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

Molecular targeted therapy of malignant pleural mesothelioma

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价